IP Library Granted Patent US 10,562,957
Granted Patent B2
US 10,562,957 · App. 15/443,884 · Granted Feb 18, 2020

Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same

Inventors: Paul Boulange (Orsay, FR); Sami Chtourou (Elancourt, FR); Stephane Boyer (Pecqueuse, FR); Roland Schmitthaeusler (Montigny le Bretonneux, FR); Bruno Padrazzi (Paris, FR)
Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
C07K14/76C07K1/34C07K14/755C07K14/765A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,562,957
App. No.
15/443,884
Granted
Feb 18, 2020
Kind
B2
Abstract

The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C. and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Claims (15)

1. A method for stabilisation of factor VIII or von Willebrand factor, and/or their recombinant equivalents, said method comprising:

adding to factor VIII or von Willebrand factor, and/or their recombinant equivalents, an albumin composition for therapeutic use obtained by purifying albumin by submitting an aqueous albumin solution, with a concentration of 15 g/L to 80 g/L, to a nanofiltration in a temperature range of 15° C. to 55° C.,

wherein the transport and binding sites of therapeutic active ingredients are available in the albumin.

2. The method according to claim 1 , wherein the nanofiltration is carried out on qualified filters having porosities of at least 13 nm.

3. The method according to claim 1 , wherein purifying albumin further comprises a step of adding a pharmaceutically acceptable salt or salt mixture to the aqueous albumin solution to provide a solution with an ionic strength in the range of 0.01 M to 0.55 M.

4. The method according to claim 3 , wherein the pharmaceutically acceptable salt is a salt of an alkali metal.

5. The method according to claim 4 , wherein the salt of an alkali metal is sodium chloride present in an amount imparting to the albumin solution an ionic strength of 0.15 M.

6. The method according to claim 1 , wherein the concentration of the aqueous albumin solution is in the range of 40 g/L to 60 g/L.

7. The method according to claim 1 , wherein the temperature of the aqueous albumin solution is between 30° C. and 55° C.

8. The method according to claim 1 , wherein the nanofiltration of the aqueous albumin solution is carried out in two successive steps on two filters with decreasing porosities, respectively.

9. The method according to claim 8 , wherein the two successive nanofiltration steps are carried out on filters with porosities of 23 to 50 nm and 15 or 20 nm, respectively.

10. The method according to claim 1 , wherein it is implemented with regenerated cellulose filters of 15 nm having a surface area of 0.01 m 2 , at a pressure not exceeding 1 bar.

11. The method according to claim 10 , wherein the pressure is in the range of 0.2 to 0.8 bar.

12. The method according to claim 1 , wherein the albumin composition comprises contains at most 1% albumin polymers with a size smaller than 100 nm.

13. The method according to claim 1 , wherein the albumin composition comprises at most 1% albumin polymers with a size smaller than 20 nm.

Assignments (2)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
Priority Claims (1)
FR 04 02001 · Feb 27, 2004 · national
Continuity (3)
Continuation 14611460 · Feb 2, 2015
Continuation 10589825
Related Publication 20170166626A1 · Jun 15, 2017